Is Xenon Pharmaceuticals Inc. (XENE) a Buy, Sell, or Hold?
NASDAQ : XENE
Xenon Pharmaceuticals Inc.
$65.42 USD
$0 (0.0%)
- Volume
- 529.96K
- Average Volume
- 1.45M
- Market Capitalization
- $6.32B
- P/E Ratio
- -13.92
- Dividend Yield
- 0.00%
- Price Target
- $89.50
- Year High
- $72.66
- Year Low
- $30.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $27.79
Company Overview
NASDAQ
Ian C. Mortimer
Biotechnology
Healthcare
XENE
316
CA
USD
Liquidity Metrics
0.01
27.79
27.79
13.71
0.00
Sales & Valuation
$7.5M
0.00
4.27
-20.58
-3.52
Profitability
-$4.36
-$345.91M
0.00%
0.00%
-49.23%
-27.63%
P/E Metrics
-13.92
0.41
0.41
Analyst Price Target & Rating
$89.50
$100.00
$60.00
2/5
22 Analysts
-26.91%
Financial Health Scores
76.06
2/9
$1.07B
$1.39B
$48.99M
-$401.5M
Key Metrics (TTM)
$5.79B
0.00
-14.50
27.79
-49.23%
-30.44%
-6.71%
-4.86%
-27 days
Company Executives
| Name | Title |
|---|---|
| James R. Empfield | Executive Vice President of Drug Discovery |
| Ian C. Mortimer | President, Chief Executive Officer & Director |
| Andrea DiFabio | Chief Legal Officer & Corporate Secretary |
| Darren S. Cline | Chief Commercial Officer |
| Christopher John Kenney | Chief Medical Officer |
| Robin Sherrington | Executive Vice President of Strategy & Innovation |
| Thomas Patrick Kelly | Chief Financial Officer |
| Colleen Alabiso | Senior Vice President of Corporate Affairs |
| Matthew D. Ronsheim | Chief Operating Officer |
| Shelley McCloskey | Executive Vice President of Human Resources |
| Gilbert | Senior Director |
Poll Results
No votes yet today — be the first to share your view!
About Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epil ... eptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution
2026-07-16 07:20:34
Xenon Pharmaceuticals (XENE) is transitioning into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform and strong Phase 3 epilepsy data. XENE's lead candidate, azetukalner, showed robust efficacy in refractory focal onset seizures and is progressing toward a Q3 2026 NDA filing. The company has a cash runway through 2029, supporting ongoing Phase 3 trials in MDD, bipolar depression, and pain, and is building a commercial infrastructure.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 16:01:00
VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 20,200 share options and 11,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of July 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
2026-06-23 12:00:38
XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-29 16:01:00
VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs).
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-29 16:01:00
VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 28, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
2026-05-18 13:24:01
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
2026-05-14 16:40:55
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Q1 Earnings Call Highlights
2026-05-09 04:07:32
Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first quarter.
Frequently Asked Questions
-
What is the current Xenon Pharmaceuticals Inc. (XENE) stock price?
-
Xenon Pharmaceuticals Inc.(NASDAQ:XENE) stock price is $65.42 in the last trading session. During the trading session, XENE stock reached the peak price of $72.66 while $30 was the lowest point it dropped to. The percentage change in XENE stock occurred in the recent session was 0.0% while the dollar amount for the price change in XENE stock was $0.
-
XENE's industry and sector of operation?
-
The NASDAQ listed XENE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of XENE?
-
James R. Empfield | Executive Vice President of Drug Discovery
Ian C. Mortimer | President, Chief Executive Officer & Director
Andrea DiFabio | Chief Legal Officer & Corporate Secretary
Darren S. Cline | Chief Commercial Officer
Christopher John Kenney | Chief Medical Officer -
How many employees does XENE have?
-
Number of XENE employees currently stands at 316. XENE operates from 3650 Gilmore Way, Burnaby, BC V5G 4W8, CA.
-
Link for XENE official website?
-
Official Website of XENE is: https://www.xenon-pharma.com
-
How do I contact XENE?
-
XENE could be contacted at phone #16044843300 and can also be accessed through its website. XENE operates from 3650 Gilmore Way, Burnaby, BC V5G 4W8, CA.
-
How many shares of XENE are traded daily?
-
The average number of XENE shares traded daily for last 3 months was 1.45M.
-
What is the market cap of XENE currently?
-
The market value of XENE currently stands at $6.32B with its latest stock price at $65.42